Inhibrx To Share Clinical Insights on Ozekibart for Colorectal Cancer

Inhibrx Plans Live Webcast for Ozekibart Update

Inhibrx Biosciences, Inc. (Nasdaq: INBX), a biopharmaceutical firm in clinical stages, is set to host a live webcast on April 21, 2026. This presentation aims to provide a crucial clinical update on Ozekibart (INBRX-109) in patients suffering from late-stage colorectal cancer, particularly those with locally advanced or metastatic unresectable colorectal cancer (CRC). The webcast is scheduled for 1:30 p.m. PT and presents a unique opportunity for investors and stakeholders to gain insights into the company’s progress in oncology.

Joining the Webcast

Investors can easily participate in the live event by accessing the link here or by calling (1-888-880-3330). When calling, it’s advised to mention Inhibrx Biosciences, Inc. along with the conference ID 9536529 for reference. For those unable to attend the live session, a link to the presentation will be available on Inhibrx's website in the 'Events and Presentations' section for 60 days post-event.

Overview of Ozekibart (INBRX-109)

Ozekibart is engineered to be a tetravalent agonist antibody that activates death receptor 5 (DR5). This mechanism is significant as it aims to induce tumor-specific cell apoptosis through DR5 activation. Earlier in January 2021, the FDA granted Ozekibart a Fast Track designation for treating metastatic or unresectable conventional chondrosarcoma. The following November, it received orphan drug designation also for chondrosarcoma, pointing to its potential in addressing hard-to-treat conditions.

Recent Clinical Trial Highlights

Inhibrx initiated a randomized, blinded, placebo-controlled trial of Ozekibart in 2021, focusing on metastatic, unresectable conventional chondrosarcoma. The trial included 206 participants at 67 global sites, and results announced in October 2025 showed a promising achievement. The ChonDRAgon study successfully met its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival (PFS) for patients receiving Ozekibart compared to those on placebo. Specifically, there was a remarkable 52% reduction in the risk of disease progression or death, elevating median PFS from 2.66 months (for placebo) to 5.52 months (for Ozekibart), establishing it as the first investigational therapy to offer such robust results in a randomized setting for this cancer type.

Future Exploration Plans

Inhibrx is ambitiously expanding its exploration of Ozekibart beyond chondrosarcoma. Currently, ongoing Phase 1/2 trials are investigating its usage in colorectal cancer alongside the FOLFIRI regimen, while also considering combination treatments with irinotecan/temozolomide for Ewing sarcoma, along with various other malignancies. This strategic expansion could broaden treatment options not only for colorectal cancer but also for patients suffering from other significant tumor types.

About Inhibrx Biosciences

Established in January 2024, Inhibrx Biosciences focuses on creating a diverse array of novel biologic therapeutic solutions. This clinical-stage biopharmaceutical company leverages innovative protein engineering to tackle complex disease biology effectively. Notably, it entered the market under the umbrella of Inhibrx, Inc. post a series of internal restructuring transactions that facilitated the acquisition of crucial assets. Currently, its promising pipeline includes Ozekibart and another investigational medicine, INBRX-106, aimed at optimizing therapeutic efficacy through a sophisticated multivalent approach. More insights are available at Inhibrx's website.

Conclusion

Ozekibart represents a significant advancement in therapeutic options for challenging cancer types, especially in a clinical landscape often dominated by limited choices. The upcoming webcast promises to shed light on not only the latest findings but also on the future trajectory of Inhibrx as it navigates this evolving therapeutic space. For interested parties, participation is highly encouraged to stay informed on the latest developments.